Dicerna Pharmaceuticals Growth, Revenue, Number of Employees and Funding

Overview

Location:
Boston, MA USA
Total Funding:$373M
Industry:Pharma
Founded:N/A
Lead Investor(s):Eli Lilly
Press

City Ranking

Industry Ranking

State Ranking

Growjo 10k Ranking

Estimated Revenue & Financials

  • Dicerna Pharmaceuticals's estimated revenue is currently $6.2M per year.
  • Dicerna Pharmaceuticals received $100.0M in venture funding in October 2018.
  • Dicerna Pharmaceuticals's estimated revenue per employee is $37683
  • Dicerna Pharmaceuticals's total funding is $373M.

Employee Data

  • Dicerna Pharmaceuticals has 164 Employees.
  • Dicerna Pharmaceuticals grew their employee count by 98% last year.
  • Dicerna Pharmaceuticals currently has 26 job openings.

Executive Contacts

NameTitle
Bob BrownChief Scientific Officer SVP,
Doug FambroughCEO/President
Nancy GoodmanDirector, Clinical Operations
Shanthi GaneshAssociate Director, Pre Clinical Oncology
Jean KaufmanVice President Human Resources
Jack GreenChief Financial Officer
Nicole KopeckyDirector of Financial Reporting
Ralf RosskampChief Medical Officer
Charles ForsythAssociate Director, Corporate Financial & Strategic Planning
Hank DudekSenior Director, Research

What Is Dicerna Pharmaceuticals?

Dicerna is working to improve the lives of people suffering from rare diseases, chronic liver diseases, cardiovascular disease, and viral liver infectious diseases. We discover and develop innovative therapies to stop or turn off destructive disease processes by silencing the genes underlying these processes. Our proprietary, next-generation technology, known as RNA interference or RNAi, uses the body's natural biological pathways to silence genes in the liver with a high degree of selectivity and specificity. By targeting genes that contribute to serious diseases, we seek to address the underlying cause of illness and restore health. Dicerna is advancing a growing pipeline of product candidates, with our DCR-PHXC lead program in preclinical development for the treatment of a progressive and debilitating rare disease called primary hyperoxaluria, or PH.We expect to launch additional GalXC programs in HBV, cardiovascular disease targeting PCSK9, and another in an undisclosed genetic rare disease. We expect to launch two additional GalXCTM programs in 2016, including one in cardiovascular disease targeting PCSK9 and another in an undisclosed genetic rare disease. We also have the capacity to launch up to three additional programs annually, with the intent to advance five programs into the clinic by the end of 2019. OUR PEOPLE ARE OUR STRENGTH. Dicerna brings together talented experts in biology, chemistry, clinical science and medicine. With decades of scientific and technical experience focused on RNAi technology, our team has the knowledge and experience needed to discover, develop and commercialize safe and effective therapies for patients with serious unmet medical needs. Our purpose is clear: delivering life-changing therapies as efficiently as possible to meet the urgent needs of people living with debilitating genetic diseases.

keywords:Biotechnology,Healthcare,Pharmaceuticals

164

Number of Employees

$6.2M

Revenue (est)

26

Current Jobs

98%

Employee Growth %

$373M

Total Funding

N/A

Valuation

N/A

Accelerator

B2B

Type

Similar Companies

NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
Vita Data Scien...
$7.8M4250%
Veristat
$38M22015%
TESARO
$176.1M9376%
Agios Pharmaceu...
$111.2M59214%
Adelphi Values
$24.7M1326%
Acer Therapeuti...
$5M3918%$29M
Opus Regulatory
$8.2M4429%
Boston Biomedic...
$29.9M15910%
Orbis Clinical
$7.4M4018%
Long Term Pharm...
$10.3M5510%

Dicerna Pharmaceuticals News

09/03/2019 - Dicerna™ Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

CAMBRIDGE, Mass.--(BUSINESS WIRE)--. Dicerna™ Pharmaceuticals, Inc. (DRNA) (the “Company” or “Dicerna”), a leading developer of ...

09/08/2019 - Dicerna Pharmaceuticals' (NASDAQ:DRNA) Buy Rating ...

Chardan Capital reaffirmed their buy rating on shares of Dicerna Pharmaceuticals (NASDAQ:DRNA) in a research note issued to investors on ...

09/03/2019 - Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) Stock Is Shorted Less

It dropped, as 14 investors sold Dicerna Pharmaceuticals, Inc. shares while 20 reduced holdings. 24 funds opened positions while 30 raised ...

Dicerna Pharmaceuticals Funding

DateAmountRoundLead InvestorsReference
2008-07-16$8.4MAOxford Bioscience Partners, Skyline VenturesArticle
2010-08-12$25.0MBDomain AssociatesArticle
2010-10-22$4.0MBSR OneArticle
2013-08-02$60.0MCRA CapitalArticle
2015-05-20$UndisclosedUndisclosedJefferies LLCArticle
2017-03-31$70.0MUndisclosedBain Capital Life SciencesArticle
2017-12-15$UndisclosedUndisclosedStifelArticle
2018-09-10$115.0MUndisclosedCitigroupArticle
2018-10-31$100.0MUndisclosedEli LillyArticle

Dicerna Pharmaceuticals Executive Hires

DateNameTitleReference
2010-05-07Douglas M. FambroughCEOArticle
2012-01-05James B. WeissmanChief Business OfficerArticle
2014-04-03Pankaj BhargavaChief Medical OfficerArticle
2014-12-18Theodore T. AshburnSVP Product Strategy /OperationsArticle
2015-12-16John GreenInterim CFOArticle
2016-04-19John B. GreenCFOArticle
2017-06-09Ralf RosskampChief Medical OfficerArticle
2019-02-22Regina PagliaSVP Human ResourcesArticle
2019-02-25Douglas FambroughPresident and Chief Executive OfficerArticle